Themis Medicare Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
THEMISMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Themis Medicare's board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025. Standalone revenue grew 6.2% YoY to Rs. 40,551 lakhs, but profit after tax dipped 3.3% to Rs. 2,392 lakhs (EPS Rs. 2.60). The Q4 was weak, with standalone revenue falling 26.7% YoY to Rs. 7,170 lakhs and swinging to a loss of Rs. 774 lakhs. On a consolidated basis, PAT dropped 31.5% to Rs. 2,983 lakhs, mainly because the share of profits from associates/JV (Richter Themis Medicare) halved to Rs. 1,881 lakhs. The board recommended a final dividend of Rs. 0.50 per share (50%) and approved a new MoU with JV partner Gedeon Richter Plc. for a USD 440,000 management fee. The audit report is unmodified, and the amalgamation with Gujarat Themis Biosyn (swap ratio 118:100) remains pending NCLT/SEBI approvals.
Mixed picture for shareholders: steady full-year revenue and a modest dividend (yield ~0.6% at recent prices) are positives, but a sharp Q4 slowdown, a quarterly loss, and weaker JV earnings weigh on near-term sentiment. The pending GTBL merger and JV management fee are incremental positives to watch.